Clinical Trials Network - Southwest Node :: Center on Alcohol, Substance use, And Addictions (CASAA)

Clinical Trials Network - Southwest Node

National Institute on Drug Abuse Clinical Trials Network (CTN)

CTNLargeMap

UNM is proud to serve as a node of the National Institute on Drug Abuse Clinical Trials Network (CTN)

Principal Investigators:

Kimberly Page, PhD, MPH, MS

Associate Directors

Valerie Carrejo, MD
Snehal Bhatt, MD
Scott Tonigan, PhD
Jennifer Hettema, PhD

Funding Agency

National Institute on Drug Abuse

Division of Epidemiology, Biostatistics, and Preventive Medicine

rib-building Department of Internal Medicine
MSC10-5550
1 University of New Mexico
Albuquerque, New Mexico 87131
Phone: 505-925-4621
SouthwestCTN@salud.unm.edu

CTN Information

For CTN related Publications and Presentations please visit CTN Dissemination Library at http://ctndisseminationlibrary.org/

CTN Archive Page

Brain & Behavioral Health Institute and NIDA Southwest CTN Node Presents:

Targeting Solutions for Future Clinical Pain Management

September 23rd, 2021, 4:00-5:00pm

Download Flyer

Abstract:

Novel scFv antibodies and patient samples are being characterized in pre-clinical studies designed to target potential chronic pain therapies. The scFvs are being validated with animal behavioral and a human stem cell platform. Using a combination of electrophysiological, molecular and cell biology approaches, samples (CSF and blood) from chronic pain patients have a primary focus on how this might influence nociceptor excitability. We hope that these studies will lead to the discovery of novel targets for treating specific chronic pain conditions.

Current Studies with Southwest CTN Involvement

Study	Current Status	Objectives of the study	SW CTN Role
CTN-0080: MOMs	Implementation	To evaluate the impact of treating opioid use disorder in pregnant women with BUP-XR, compared to BUP-SL, on maternal-infant outcomes.	Study site
CTN-0096: MOUDX	Phase 1	To develop and test a culturally-centered program to support the integration of medications (BUP, XR-naltrexone) to treat OUD among AI/AN in primary care and addiction treatment clinics.	Lead node
CTN-0099: ED-INNOVATION	Pre-implementation	To evaluate implementation of emergency department (ED)-initiated BUP in a large number of sites; compare extended release (XR)-BUP with sublingual (SL) BUP in ED patients with untreated OUD; and track treatment follow-up outside of the ED.	2 study sites
CTN-0100: RDD	Site selection	To 1) test strategies to improve MOUD treatment retention and improve outcomes among patients who have been successfully stabilized on MOUD and want to stop MOUD; and 2) identify predictors of successful outcome and develop a stage model of relapse risk.	Site survey submitted
CTN-0102: Rural MOUD	Site selection	To 1) test expanded treatment access to improve retention on MOUD in highly impacted rural areas, 2) evaluate comparative effectiveness between office-base opioid treatment (OBOT) vs OBOT + telemedicine (TM) in 30 sites.	Site survey submitted

Other Currently Active CTN Studies

Study	Current Status	Objectives of the study
CTN-0098: EXHIT-ENTRE	Site Selection	This study will examine whether 1) in hospitals with addiction medicine consultation services, hospital-initiated extended release buprenorphine (XR-BUP), compared to other OUD medications, results in increased OUD treatment engagement following hospital discharge; and 2) training hospitals without such consultation services on best practices for initiating OUD medication using consultation service hubs improves medication uptake in hospitals and following discharge.
CTN-0101: STOP	Site Selection	This study will test the efficacy of a primary care Subthreshold Opioid Use Disorder Prevention (STOP) intervention to reduce unhealthy opioid use and examine the impact of STOP on progression to moderate-severe OUD, overdose risk behavior, and overdose events in adults with unhealthy use of illicit/prescribed opioids.

Upcoming Studies

Study	Current Status	Objectives of the study
CTN-0103	Protocol development	To expand clinical research training in evidence-based quality improvement methods. Participating primary care practices will be trained in the 1) use of a study-developed toolkit of research and evaluation quality improvement methods intended to expand provider knowledge and performance in the delivery of evidence-based MOUD, 2) systematic tracking of standardized outcome metrics, and 3) sharing of standardized data with other LC members so that practices can use this empirical information to refine their care model over time.
CTN-0104	Protocol development	To address stigma around treating OUD by conducting a national provider survey of the general practice workforce. Specific aims are: (1) to define the scope of provider stigma and identify barriers to treating opioid use disorders in medical care and dental care settings, and (2) to investigate what potential intervention strategies are needed to address identified barriers to improve the delivery of opioid treatment in primary care settings across the United States.
CTN-0105	Protocol development	To use mixed methods to study pharmacists’ knowledge of, attitudes about, and intention to provide patient care and services for Screening for substance use, Brief Intervention, and Referral to Treatment (SBIRT) for substance use disorders (SUDs) and Medication treatment for Opioid Use Disorders (MOUD). The findings will inform barriers and facilitators related to pharmacist-provided services and patient care for SBIRT and MOUD.
CTN-0106	Protocol development	To conduct a series of analyses with data from the Brief Addiction Monitor (BAM), which has been selected for a national MBC initiative within the Veteran’s Administration. The goal of the work will be to derive and validate two new scales from the BAM. One scale is intended for use in opioid use disorder (OUD) specialty care programs. The second version is intended for use in primary care based MOUD.
CTN-0107	Protocol development	A 3-site, randomized controlled trial using Peer Recovery Coaches trained in FORCE (FAVOR Overdose Recovery Coaching Evaluation), who will engage with opioid overdose survivors in the emergency department to get permission to contact them and engage participants in care and develop a patient-centered recovery plan. The FORCE intervention will be tailored to the participant's needs and will continue for 12 months after enrollment. This intervention will be compared to Treatment as Usual (TAU) in which overdose survivors receive referral to treatment. Outcomes include engagement in formal OUD treatment between groups, retention in treatment, and number of overdoses after enrollment.

CTNProtocolSubmission

Center on Alcohol, Substance use, And Addictions (CASAA)